Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$10.27
-6.8%
$10.78
$8.63
▼
$26.18
$718.69M-0.84410,693 shs142,685 shs
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$7.28
-3.8%
$7.01
$3.53
▼
$11.29
$224.60M1.34434,611 shs204,412 shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
0.00%+5.45%+21.77%-24.88%-16.77%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
0.00%-28.58%+31.20%+2.30%+28.74%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$10.27
-6.8%
$10.78
$8.63
▼
$26.18
$718.69M-0.84410,693 shs142,685 shs
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$7.28
-3.8%
$7.01
$3.53
▼
$11.29
$224.60M1.34434,611 shs204,412 shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
0.00%+5.45%+21.77%-24.88%-16.77%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
0.00%-28.58%+31.20%+2.30%+28.74%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
2.67
Moderate Buy$45.25340.60% Upside
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
2.60
Moderate Buy$32.25342.99% Upside

Current Analyst Ratings Breakdown

Latest DTIL and DBVT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/3/2026
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
Reiterated RatingSell (D-)
10/30/2026
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Reiterated RatingBuy
10/30/2026
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Lower Price TargetBuy$51.00 ➝ $46.00
10/29/2026
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Reiterated RatingMarket Outperform
10/29/2026
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Lower Price TargetMarket Outperform$55.00 ➝ $47.00
10/15/2026
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Reiterated RatingSell (E+)
9/30/2026
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Reiterated RatingMarket Outperform
9/10/2026
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Reiterated RatingOverweight
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$5.64M114.50N/AN/A$2.36 per share4.35
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$34.26M5.94N/AN/A$1.85 per share3.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$146.95M-$3.01N/AN/AN/A-5,392.17%-120.95%-88.35%N/A
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
-$45.72M-$1.24N/AN/AN/A-96.73%-56.69%-27.63%N/A

Latest DTIL and DBVT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
-$0.85-$0.28+$0.57-$0.28$1.38 millionN/A
10/28/2026Q3 2026
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$0.2903-$0.70-$0.4098-$0.70$0.56 million$1.60 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/AN/AN/AN/AN/A
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A
3.24
3.24
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
0.43
10.47
10.47

Institutional Ownership

CompanyInstitutional Ownership
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
71.74%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
37.99%

Insider Ownership

CompanyInsider Ownership
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
1.06%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
12562.88 million62.21 millionOptionable
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
6927.94 million27.18 millionOptionable

Recent News About These Companies

Precision BioSciences raises $125M in offering
HC Wainwright Has Bullish Estimate for DTIL FY2026 Earnings
Precision BioSciences Inc (DTIL)

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBV Technologies stock logo

DBV Technologies NASDAQ:DBVT

$10.27 -0.75 (-6.81%)
Closing price 04:00 PM Eastern
Extended Trading
$10.26 -0.01 (-0.10%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Precision BioSciences stock logo

Precision BioSciences NASDAQ:DTIL

$7.28 -0.29 (-3.83%)
Closing price 04:00 PM Eastern
Extended Trading
$7.29 +0.01 (+0.12%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.